ArticleJournal of Ayurveda and integrative medicine
Three years of chemotherapy tolerance with concurrent Ayurvedic treatment in a metastatic lung adenocarcinoma: A case report.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma, a prevalent form of non-small cell lung cancer, presents significant challenges due to its advanced stage at diagnosis and heterogeneity. This case report details the therapeutic journey of a 61-year-old female patient diagnosed with metastatic lung adenocarcinoma, managed through an integrative approach combining chemotherapy and Ayurvedic treatment. Conventional therapy consisted of carboplatin, pemetrexed, and geftinib, targeting both primary and metastatic sites. Concurrent Ayurvedic treatment was introduced to alleviate chemotherapy-related side effects and enhance the patient's quality of life. Over a 36 months period, the patient demonstrated minimal side effects and a near-complete regression of the primary lung lesions. This case highlights the potential of Ayurvedic medicine as an adjunct to chemotherapy, offering improvements in symptom management and overall patient well-being, without obstructing the chemotherapy efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.